Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease
Claire Welsh(Institute of Medical Sciences), Paul Welsh, Stuart R. Gray(University of Glasgow), Jana Anderson(Johnson & Johnson (United Kingdom)), Jason M. R. Gill(University of Glasgow), Patrick B. Mark(University of Glasgow), Rosemary Brown(Cardiovascular Institute of the South), Jill P. Pell(University of Glasgow), Daniel Mackay(University of Glasgow), Donald M. Lyall(University of Glasgow), Carlos Celis‐Morales(Universidad Mayor), Lyn D Ferguson(Cardiovascular Institute of the South), Naveed Sattar(University of Glasgow), John G.F. Cleland(Imperial College London), James Lewsey(University of Glasgow), Pardeep S. Jhund(Copenhagen University Hospital)
Cited by 200
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
|The Lancet Diabetes & Endocrinology|2019|1.6k